Stock Events

Stock Events

Brainstorm Cell Therapeutics 

$0.59
49
-$0.04-6.51% Monday 20:44

Statistics

Day High
0.63
Day Low
0.56
52W High
1.93
52W Low
0.52
Volume
1,543
Avg. Volume
21,624
Mkt Cap
6.5M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

1AprExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.97
-0.45
0.08
0.6
Expected EPS
-0.28
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-23.25MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BCLI. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Stem
STEM
Mkt Cap164.53M
StemCells, Inc. focuses on cell-based therapeutics, directly competing in the regenerative medicine space similar to BCLI's focus on neurological conditions.
Mesoblast
MESO
Mkt Cap2.14B
Mesoblast Limited develops mesenchymal lineage adult stem cell therapies, targeting conditions that overlap with BCLI's therapeutic areas.
Biolife Solutions
BLFS
Mkt Cap1.34B
BioLife Solutions, Inc. provides bioproduction tools and services, including cell and gene therapy solutions, supporting the same market as BCLI.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG focuses on gene editing, a cutting-edge area of biotech that competes with stem cell therapy approaches in treating genetic disorders.
Vericel
VCEL
Mkt Cap1.77B
Vericel Corporation specializes in autologous cell therapies for the treatment of patients with serious diseases, including neurological conditions.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics, Inc. develops genomic therapies, offering an alternative to traditional stem cell therapies in treating genetic disorders.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, through its advanced therapy platforms, competes in the broader market of innovative treatments for neurological and other diseases.

About

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Show more...
CEO
Mr. Chaim Lebovits
Employees
27
Country
US
ISIN
US10501E3009

Listings

OTC Link
US
BCLI

0 Comments

Share your thoughts

FAQ

What is Brainstorm Cell Therapeutics stock price today?▼
The current price of BCLI is $0.59 USD — it has decreased by -6.51% in the past 24 hours. Watch Brainstorm Cell Therapeutics stock price performance more closely on the chart.
What is Brainstorm Cell Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Brainstorm Cell Therapeutics stocks are traded under the ticker BCLI.
Is Brainstorm Cell Therapeutics stock price growing?▼
BCLI stock has risen by +1.18% compared to the previous week, the month change is a -3.45% fall, over the last year Brainstorm Cell Therapeutics has showed a -67.9% decrease.
What is Brainstorm Cell Therapeutics market cap?▼
Today Brainstorm Cell Therapeutics has the market capitalization of 6.5M
When is the next Brainstorm Cell Therapeutics earnings date?▼
Brainstorm Cell Therapeutics is going to release the next earnings report on April 01, 2026.
What were Brainstorm Cell Therapeutics earnings last quarter?▼
BCLI earnings for the last quarter are -0.19 USD per share, whereas the estimation was -0.37 USD resulting in a +48.65% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Brainstorm Cell Therapeutics revenue for the last year?▼
Brainstorm Cell Therapeutics revenue for the last year amounts to 0 USD.
What is Brainstorm Cell Therapeutics net income for the last year?▼
BCLI net income for the last year is -23.25M USD.
How many employees does Brainstorm Cell Therapeutics have?▼
As of February 03, 2026, the company has 27 employees.
In which sector is Brainstorm Cell Therapeutics located?▼
Brainstorm Cell Therapeutics operates in the Health Care sector.
When did Brainstorm Cell Therapeutics complete a stock split?▼
The last stock split for Brainstorm Cell Therapeutics was on October 01, 2024 with a ratio of 1:15.
Where is Brainstorm Cell Therapeutics headquartered?▼
Brainstorm Cell Therapeutics is headquartered in New York, US.